Recruiting
Interstitial lung disease+1
RecruitingInvestigational
A study to evaluate the effectiveness of BI 1015550 in people with lung abnormalities and a family history of pulmonary fibrosis
Investigational
- Disease:Interstitial lung diseasePulmonary fibrosis
- Substances:Bi 10155501-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol
Countries:
Belgium
Belgium- Participants:18–64 years · 65+ years · Healthy volunteers
- Substances:Bi 1015550
- Sponsor:Boehringer Ingelheim International GmbH
